JOSTRA RETROGRADE CARDIOPLEGIA CANNULAE

K014303 · Jostra AG · DWF · Mar 26, 2002 · Cardiovascular

Device Facts

• Record ID: K014303
• Device Name: JOSTRA RETROGRADE CARDIOPLEGIA CANNULAE
• Applicant: Jostra AG
• Product Code: DWF · Cardiovascular
• Decision Date: Mar 26, 2002
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.4210
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Jostra Retrograde Cardioplegia Cannulas are designed to infuse blood or cardioplegia arrest solution to the myocardial tissue retrograde via the coronary sinus during cardiopulmonary bypass up to 6 hours or less.

Device Story

Jostra Retrograde Cardioplegia Cannula is a single-use, sterile device for delivering blood or cardioplegia arrest solution to myocardial tissue via the coronary sinus during extracorporeal circulation. Device consists of 14 Fr. polyvinyl chloride (PVC) cannula with integrated balloon, optional pressure monitoring lines, and choice of stiff or flexible stylets. Operated by clinicians during cardiopulmonary bypass procedures. Provides controlled delivery of cardioplegic solution to achieve myocardial arrest. Benefits include localized delivery of arrest solution to protect heart muscle during bypass surgery.

Clinical Evidence

No clinical data. Substantial equivalence supported by bench testing and in-vitro performance evaluation. Bench testing included flow-pressure curves, kink resistance, bond strength, and leakage tests. In-vitro testing assessed effects on cellular components.

Technological Characteristics

Materials: Polyvinyl chloride (PVC). Dimensions: 14 Fr. Features: Integrated balloon, optional pressure monitoring lines, stiff or flexible stylets. Principle: Passive infusion cannula. Sterilization: Sterile, single-use.

Indications for Use

Indicated for patients undergoing cardiopulmonary bypass requiring infusion of blood or cardioplegia arrest solution to myocardial tissue via the coronary sinus for durations of 6 hours or less.

Regulatory Classification

Identification

A cardiopulmonary bypass vascular catheter, cannula, or tubing is a device used in cardiopulmonary surgery to cannulate the vessels, perfuse the coronary arteries, and to interconnect the catheters and cannulas with an oxygenator. The device includes accessory bypass equipment.

Predicate Devices

• Medtronic DLP Retrograde Cardioplegia Cannula

Submission Summary (Full Text)

{0}------------------------------------------------

### MAR 2 6 2002

#### 510 (K) Summary

Submitter:

Jostra AG Hechinger Straße 38 72145 Hirrlingen Germany

Contact Person:

Kathleen Johnson Phone: [phone] [phone] Fax:

December 21, 2001 Date Prepared:

Device Trade Name:

Common/Usual Name: Retrograde Cardioplegia Cannula

Classification Names:

### Cardiopulmonary Bypass Vascular Cannula Cardiopulmonary Bypass Adaptor, Stopcock, Manifold, or Fitting Catheter Stylet Piston Svringe

Jostra Retrograde Cardioplegia Cannula

Predicate Device: Medtronic DLP Retrograde Cardioplegia Cannula

### Device Description:

The Jostra Retrograde Cardioplegia Cannulas are single, sterile devices for single use only and not to be resterilized by the user. The cannulas are to be used to infuse blood or cardioplegia arrest solution retrograde via the coronary sinus during extracorporeal circulation. The cannulas are made from polyvinyl chloride (PVC) in size 14 Fr. with a variety of balloons, with or without pressure monitoring lines and a choice of stiff or flexible stylets.

### Indications for use:

The Jostra Retrograde Cardioplegia Cannulas are designed to infuse blood or cardioplegia arrest solution to the myocardial tissue retrograde via the coronary sinus during cardiopulmonary bypass up to 6 hours or less.

Statement of Technical Characteristics Comparison:

The Jostra Retrograde Cardioplegia Cannulas have the same intended use as the Medtronic DLP Retrograde Cardioplegia Cannulas. Comparative testing has demonstrated that these differences do not affect safety and effectiveness.

{1}------------------------------------------------

Non-Clinical Testing:

Biocompatibility and performance testing was performed to demonstrate substantial equivalency to the predicate device.

Performance testing included:

Flow-Pressure curves Kink Resistance Bond Strength Leakage Test

Additionally, in-vitro testing was performed to determine the effects on cellular components.

#### Conclusion:

Performance, and in-vitro testing demonstrate that the Jostra Retrograde Cardioplegia Cannulae are "substantially equivalent" to the predicate devices in intended use, principles of operation, materials, design, and performance.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of the department's name in a circular arrangement around a symbol. The symbol is a stylized representation of a human figure embracing a globe. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

# MAR 2 6 2002

Ms. Kathy Johnson Regulatory Affairs, Submission Manager JOSTRA® AG c/o JOSTRA-Bentley Corporation 478 Media Road Oxford, PA 19363

Re: K014303

Trade Name: Jostra Retrograde Cardioplegia Cannula Regulation Number: 21 CFR 4210 Regulation Name: Cardiopulmonary bypass vascular catheter, cannula, or tubing. Regulatory Class: Class II (two) Product Code: DWF Dated: December 21, 2001 Received: December 31, 2001

Dear Ms. Johnson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality

{3}------------------------------------------------

Page 2 - Ms. Kathy Johnson

systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Control provided in the marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally premaince notification " results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Toganalers information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Dak Telle

Bram D. Zuckerman, M.D. Acting Director Division of Cardiovascular And Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Page 1 of 1

510(k) Number:

.

Device Name: Jostra Retrograde Cardioplegia Cannulas

#### Indications for Use

indications for USE
The Jostra Retrograde Cardioplegia Cannulas are designed for the coronary The Jostra Rerograde Cardioplegia Cannarao al Sissue retrograde via the coronary
or cardioplegia arrest solution to the myocardial tissue retograde via the coronary of Cardloplegia an ook default to are bypass up to 6 hours or less.

## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Division of Cardiovascular & Respiratory Devices
510(k) Number R014305

(Optional Format 3-10-98)

**Prescription Use**
(Per 21 CFR 801.109)